JNNP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hershey, T
Right arrow Articles by Perlmutter, J S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hershey, T
Right arrow Articles by Perlmutter, J S
Related Collections
Right arrow Interventional radiology
Right arrow Drugs: central nervous system (not psychiatric)
Right arrow Parkinson's disease
Journal of Neurology Neurosurgery and Psychiatry 2003;74:844-851
© 2003 BMJ Publishing Group


PAPER

Long term treatment and disease severity change brain responses to levodopa in Parkinson’s disease

T Hershey1,3, K J Black1,2,3, J L Carl3, L McGee-Minnich3, A Z Snyder2,3, J S Perlmutter2,3,4

1 Department of Psychiatry, Washington University School of Medicine, USA
2 Department of Radiology, Washington University School of Medicine
3 Department of Neurology, Washington University School of Medicine
4 Department of Anatomy and Neurobiology, Washington University School of Medicine

Correspondence to:
Correspondence to:
Dr J S Perlmutter, Campus Box 8225,4525 Scott Avenue, St Louis, MO 63110, USA;
joel{at}npg.wustl.edu

Objectives: Degeneration of nigrostriatal neurons and subsequent striatal dopamine deficiency produce many of the symptoms of Parkinson disease (PD). Initially restoration of striatal dopamine with oral levodopa provides substantial benefit, but with long term treatment and disease progression, levodopa can elicit additional clinical symptoms, reflecting altered effects of levodopa in the brain. The authors examined whether long term treatment affects the brain’s response to levodopa in the absence of these altered clinical responses to levodopa.

Methods: Positron emission tomography (PET) measurements were used of brain-blood flow before and after an acute dose of levodopa in three groups: PD patients treated long term with levodopa without levodopa induced dyskinesias, levodopa naive PD patients, and controls.

Results: It was found that the PD group treated long term responded to acute levodopa differently from controls in left sensorimotor and left ventrolateral prefrontal cortex. In both regions, the treated PD group had decreased blood flow whereas the control group had increased blood flow in response to levodopa. Levodopa naive PD patients had little or no response to levodopa in these regions. Within the treated PD group, severity of parkinsonism correlated with the degree of abnormality of the sensorimotor cortex response, but not with the prefrontal response.

Conclusions: It is concluded that long term levodopa treatment and disease severity affect the physiology of dopaminergic pathways, producing altered responses to levodopa in brain regions associated with motor function.


Keywords: Parkinson’s disease; cerebral blood flow; dopamine; levodopa; positron emission tomography

Abbreviations: PD, Parkinson’s disease; PET, positron emission tomography




This article has been cited by other articles:


Home page
J. Neurosci.Home page
S. Hirano, K. Asanuma, Y. Ma, C. Tang, A. Feigin, V. Dhawan, M. Carbon, and D. Eidelberg
Dissociation of Metabolic and Neurovascular Responses to Levodopa in the Treatment of Parkinson's Disease
J. Neurosci., April 16, 2008; 28(16): 4201 - 4209.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2003 by the BMJ Publishing Group Ltd.